keyword
MENU ▼
Read by QxMD icon Read
search

Vbloc

keyword
https://www.readbyqxmd.com/read/27576578/vagal-blocking-for-obesity-control-a-possible-mechanism-of-action
#1
Helene Johannessen, David Revesz, Yosuke Kodama, Nikki Cassie, Karolina Skibicka, Perry Barrett, Suzanne Dickson, Jens Holst, Jens Rehfeld, Geoffrey van der Plasse, Roger Adan, Bård Kulseng, Elinor Ben-Menachem, Chun-Mei Zhao, Duan Chen
BACKGROUND: Recently, the US FDA has approved "vagal blocking therapy or vBLoc® therapy" as a new treatment for obesity. The aim of the present study was to study the mechanism-of-action of "VBLOC" in rat models. METHODS: Rats were implanted with VBLOC, an intra-abdominal electrical device with leads placed around gastric vagal trunks through an abdominal incision and controlled by wireless device. Body weight, food intake, hunger/satiety, and metabolic parameters were monitored by a comprehensive laboratory animal monitoring system...
August 30, 2016: Obesity Surgery
https://www.readbyqxmd.com/read/27506803/two-year-outcomes-of-vagal-nerve-blocking-vbloc-for-the-treatment-of-obesity-in-the-recharge-trial
#2
Caroline M Apovian, Sajani N Shah, Bruce M Wolfe, Sayeed Ikramuddin, Christopher J Miller, Katherine S Tweden, Charles J Billington, Scott A Shikora
BACKGROUND: The ReCharge Trial demonstrated that a vagal blocking device (vBloc) is a safe and effective treatment for moderate to severe obesity. This report summarizes 24-month outcomes. METHODS: Participants with body mass index (BMI) 40 to 45 kg/m(2), or 35 to 40 kg/m(2) with at least one comorbid condition were randomized to either vBloc therapy or sham intervention for 12 months. After 12 months, participants randomized to vBloc continued open-label vBloc therapy and are the focus of this report...
August 10, 2016: Obesity Surgery
https://www.readbyqxmd.com/read/27048437/effect-of-vagal-nerve-blockade-on-moderate-obesity-with-an-obesity-related-comorbid-condition-the-recharge-study
#3
John M Morton, Sajani N Shah, Bruce M Wolfe, Caroline M Apovian, Christopher J Miller, Katherine S Tweden, Charles J Billington, Scott A Shikora
BACKGROUND: Vagal nerve blockade (vBloc) therapy was shown to be a safe and effective treatment for moderate to severe obesity. This report summarizes the safety and efficacy of vBloc therapy in the prespecified subgroup of patients with moderate obesity. METHODS: The ReCharge Trial is a double-blind, randomized controlled clinical trial of participants with body mass index (BMI) of 40-45 or 35-40 kg/m(2) with at least one obesity-related comorbid condition. Participants were randomized 2:1 to implantation with either a vBloc or sham device with weight management counseling...
May 2016: Obesity Surgery
https://www.readbyqxmd.com/read/26959077/role-of-the-vagus-nerve-in-the-development-and-treatment-of-diet-induced-obesity
#4
Guillaume de Lartigue
This review highlights evidence for a role of the vagus nerve in the development of obesity and how targeting the vagus nerve with neuromodulation or pharmacology can be used as a therapeutic treatment of obesity. The vagus nerve innervating the gut plays an important role in controlling metabolism. It communicates peripheral information about the volume and type of nutrients between the gut and the brain. Depending on the nutritional status, vagal afferent neurons express two different neurochemical phenotypes that can inhibit or stimulate food intake...
October 15, 2016: Journal of Physiology
https://www.readbyqxmd.com/read/26525980/erratum-to-intermittent-vagal-nerve-block-for-improvements-in-obesity-cardiovascular-risk-factors-and-glycemic-control-in-patients-with-type-2-diabetes-mellitus-2-year-results-of-the-vbloc-dm2-study
#5
Scott A Shikora, James Toouli, Miguel F Herrera, Bård Kulseng, Roy Brancatisano, Lilian Kow, Juan P Pantoja, Gjermund Johnsen, Anthony Brancatisano, Katherine S Tweden, Mark B Knudson, Charles J Billington
No abstract text is available yet for this article.
May 2016: Obesity Surgery
https://www.readbyqxmd.com/read/26471783/intermittent-vagal-nerve-block-for-improvements-in-obesity-cardiovascular-risk-factors-and-glycemic-control-in-patients-with-type-2-diabetes-mellitus-2-year-results-of-the-vbloc-dm2-study
#6
Scott A Shikora, James Toouli, Miguel F Herrera, Bård Kulseng, Roy Brancatisano, Lilian Kow, Juan P Pantoja, Gjermund Johnsen, Anthony Brancatisano, Katherine S Tweden, Mark B Knudson, Charles J Billington, Charles J Billingto
BACKGROUND: One-year results of the VBLOC DM2 study found that intermittent vagal blocking (VBLOC therapy) was safe among subjects with obesity and type 2 diabetes mellitus (T2DM) and led to significant weight loss and improvements in glycemic parameters and cardiovascular risk factors. Longer-term data are needed to determine whether the results are sustained. METHODS: VBLOC DM2 is a prospective, observational study of 28 subjects with T2DM and body mass index (BMI) between 30 and 40 kg/m(2) to assess mid-term safety and weight loss and improvements in glycemic parameters, and other cardiovascular risk factors with VBLOC therapy...
May 2016: Obesity Surgery
https://www.readbyqxmd.com/read/26246907/sustained-weight-loss-with-vagal-nerve-blockade-but-not-with-sham-18-month-results-of-the-recharge-trial
#7
RANDOMIZED CONTROLLED TRIAL
Scott A Shikora, Bruce M Wolfe, Caroline M Apovian, Mehran Anvari, David B Sarwer, Robert D Gibbons, Sayeed Ikramuddin, Christopher J Miller, Mark B Knudson, Katherine S Tweden, Michael G Sarr, Charles J Billington
BACKGROUND/OBJECTIVES: Vagal block therapy (vBloc) is effective for moderate to severe obesity at one year. SUBJECTS/METHODS: The ReCharge trial is a double-blind, randomized controlled clinical trial of 239 participants with body mass index (BMI) of 40 to 45 kg/m or 35 to 40 kg/m with one or more obesity-related conditions. Interventions were implantation of either vBloc or Sham devices and weight management counseling. Mixed models assessed percent excess weight loss (%EWL) and total weight loss (%TWL) in intent-to-treat analyses...
2015: Journal of Obesity
https://www.readbyqxmd.com/read/23984050/vagal-blocking-improves-glycemic-control-and-elevated-blood-pressure-in-obese-subjects-with-type-2-diabetes-mellitus
#8
MULTICENTER STUDY
S Shikora, J Toouli, M F Herrera, B Kulseng, H Zulewski, R Brancatisano, L Kow, J P Pantoja, G Johnsen, A Brancatisano, K S Tweden, M B Knudson, C J Billington
BACKGROUND: An active device that downregulates abdominal vagal signalling has resulted in significant weight loss in feasibility studies. OBJECTIVE: To prospectively evaluate the effect of intermittent vagal blocking (VBLOC) on weight loss, glycemic control, and blood pressure (BP) in obese subjects with DM2. METHODS: Twenty-eight subjects were implanted with a VBLOC device (Maestro Rechargeable System) at 5 centers in an open-label study...
2013: Journal of Obesity
https://www.readbyqxmd.com/read/22956251/the-empower-study-randomized-prospective-double-blind-multicenter-trial-of-vagal-blockade-to-induce-weight-loss-in-morbid-obesity
#9
RANDOMIZED CONTROLLED TRIAL
Michael G Sarr, Charles J Billington, Roy Brancatisano, Anthony Brancatisano, James Toouli, Lilian Kow, Ninh T Nguyen, Robin Blackstone, James W Maher, Scott Shikora, Dominic N Reeds, J Christopher Eagon, Bruce M Wolfe, Robert W O'Rourke, Ken Fujioka, Mark Takata, James M Swain, John M Morton, Sayeed Ikramuddin, Michael Schweitzer, Bipan Chand, Raul Rosenthal
BACKGROUND: Intermittent, reversible intraabdominal vagal blockade (VBLOC® Therapy) demonstrated clinically important weight loss in feasibility trials. EMPOWER, a randomized, double-blind, prospective, controlled trial was conducted in USA and Australia. METHODS: Five hundred three subjects were enrolled at 15 centers. After informed consent, 294 subjects were implanted with the vagal blocking system and randomized to the treated (n = 192) or control (n = 102) group...
November 2012: Obesity Surgery
https://www.readbyqxmd.com/read/18549888/intra-abdominal-vagal-blocking-vbloc-therapy-clinical-results-with-a-new-implantable-medical-device
#10
MULTICENTER STUDY
M Camilleri, J Toouli, M F Herrera, B Kulseng, L Kow, J P Pantoja, R Marvik, G Johnsen, C J Billington, F G Moody, M B Knudson, K S Tweden, M Vollmer, R R Wilson, M Anvari
BACKGROUND: A new medical device uses high-frequency electrical algorithms to create intermittent vagal blocking (VBLOC therapy). The aim is to assess the effects of vagal blocking on excess weight loss (EWL), safety, dietary intake, and vagal function. METHODS: An open-label, 3-center study was conducted in obese subjects (body mass index [BMI] 35-50 kg/m(2)). Electrodes were implanted laparoscopically on both vagi near the esophagogastric junction to provide electrical block...
June 2008: Surgery
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"